Gaston-Dreyfus Remi
- SEC CIK
- 0001716639
No open-market purchases or sales filed in the past year.
Current role at each company
- BNKL Bionik Laboratories Corp.Director, 10% Owneras of Jun 21, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Gaston-Dreyfus Remi as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 21, 2023 (view filing) | Jun 9 | 12 daysLate | Gaston-Dreyfus RemiDirector, 10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +180.6K | $0.60 | +$108.3K | +11.0%1.81M after | |
| Dec 13, 2021 (view filing) | Mar 26 | 262 daysLate | Gaston-Dreyfus RemiDirector, 10% Owner | PPurchaseCommon Stock, par value $0.001 per share | +135.6K | – | – | +10.6%1.42M after |